Raymond James Financial Services Advisors Inc. Has $794,000 Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Raymond James Financial Services Advisors Inc. reduced its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 3.4% in the fourth quarter, Holdings Channel reports. The institutional investor owned 6,456 shares of the specialty pharmaceutical company’s stock after selling 229 shares during the period. Raymond James Financial Services Advisors Inc.’s holdings in Jazz Pharmaceuticals were worth $794,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the business. Captrust Financial Advisors grew its holdings in shares of Jazz Pharmaceuticals by 2.4% during the first quarter. Captrust Financial Advisors now owns 3,707 shares of the specialty pharmaceutical company’s stock valued at $577,000 after buying an additional 86 shares during the last quarter. First Republic Investment Management Inc. boosted its holdings in Jazz Pharmaceuticals by 0.7% during the fourth quarter. First Republic Investment Management Inc. now owns 12,062 shares of the specialty pharmaceutical company’s stock worth $1,922,000 after purchasing an additional 88 shares during the last quarter. Daiwa Securities Group Inc. boosted its holdings in Jazz Pharmaceuticals by 2.5% during the third quarter. Daiwa Securities Group Inc. now owns 4,076 shares of the specialty pharmaceutical company’s stock worth $528,000 after purchasing an additional 100 shares during the last quarter. Utah Retirement Systems boosted its holdings in Jazz Pharmaceuticals by 0.9% during the fourth quarter. Utah Retirement Systems now owns 10,836 shares of the specialty pharmaceutical company’s stock worth $1,726,000 after purchasing an additional 100 shares during the last quarter. Finally, Johnson Investment Counsel Inc. boosted its holdings in Jazz Pharmaceuticals by 0.8% during the third quarter. Johnson Investment Counsel Inc. now owns 13,096 shares of the specialty pharmaceutical company’s stock worth $1,695,000 after purchasing an additional 110 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Stock Down 1.8 %

JAZZ opened at $108.90 on Wednesday. The company’s 50-day moving average price is $120.99 and its two-hundred day moving average price is $122.95. Jazz Pharmaceuticals plc has a twelve month low of $108.75 and a twelve month high of $146.70. The company has a quick ratio of 1.85, a current ratio of 2.24 and a debt-to-equity ratio of 1.37. The stock has a market cap of $6.86 billion, a price-to-earnings ratio of 17.79, a PEG ratio of 1.53 and a beta of 0.59.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.44 by ($0.04). Jazz Pharmaceuticals had a net margin of 10.82% and a return on equity of 31.27%. The business had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1.01 billion. As a group, equities analysts expect that Jazz Pharmaceuticals plc will post 16.24 earnings per share for the current year.

Insider Activity

In other Jazz Pharmaceuticals news, CFO Philip L. Johnson purchased 12,000 shares of the stock in a transaction dated Friday, March 1st. The shares were bought at an average price of $119.65 per share, with a total value of $1,435,800.00. Following the completion of the transaction, the chief financial officer now directly owns 27,932 shares in the company, valued at approximately $3,342,063.80. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other news, CFO Philip L. Johnson bought 12,000 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The shares were acquired at an average price of $119.65 per share, with a total value of $1,435,800.00. Following the acquisition, the chief financial officer now owns 27,932 shares of the company’s stock, valued at approximately $3,342,063.80. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Patricia Carr sold 1,936 shares of the company’s stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $119.64, for a total transaction of $231,623.04. Following the sale, the chief accounting officer now directly owns 8,364 shares in the company, valued at approximately $1,000,668.96. The disclosure for this sale can be found here. Insiders own 4.40% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. HC Wainwright cut their price target on shares of Jazz Pharmaceuticals from $204.00 to $200.00 and set a “buy” rating on the stock in a report on Thursday, March 14th. Truist Financial restated a “buy” rating and set a $200.00 price target on shares of Jazz Pharmaceuticals in a report on Wednesday, March 20th. StockNews.com upgraded shares of Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Tuesday, January 30th. UBS Group cut their price target on shares of Jazz Pharmaceuticals from $135.00 to $131.00 and set a “neutral” rating on the stock in a report on Friday, March 1st. Finally, Barclays dropped their target price on shares of Jazz Pharmaceuticals from $235.00 to $230.00 and set an “overweight” rating on the stock in a research note on Friday, March 1st. Two investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $195.08.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.